Pharmaceuticals News and Research

RSS

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

ActiveSite Pharmaceuticals, Inc., announced today the online publication of a study in the journal Diabetes that describes the effectiveness of its novel plasma kallikrein inhibitor ASP-440 in reducing blood-retinal barrier breakdown in a rodent model of diabetes.

28 Mar 2011

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that enrollment has started for the Phase 1 clinical trial testing the safety of two doses of Menerba in postmenopausal women for the treatment of menopausal hot flushes (study # MF101-008), also known as "menopausal hot flashes."

28 Mar 2011

MolecularMD and ARIAD collaborate to develop and commercialize CML, ALL diagnostic test

ARIAD Pharmaceuticals, Inc. and MolecularMD Corporation today announced an exclusive collaboration agreement in which MolecularMD will develop and commercialize a companion diagnostic test to identify the T315I mutation of the BCR-ABL gene in patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia.

28 Mar 2011

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

AVEO Pharmaceuticals, Inc. today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody pipeline will be presented during poster sessions at the American Association for Cancer Research 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla.

28 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

A.P. Pharma fourth quarter revenue decreases to $1.6 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2010 and provided a corporate update.

28 Mar 2011

University of Aberdeen, TPP enter agreement to develop novel future medicines

TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

28 Mar 2011

Anergis SA closes funding round for allergy vaccines

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

28 Mar 2011

U.S. District Court rules in favor of Watson in generic SEASONIQUE patent infringement suit

Watson Pharmaceuticals, Inc., a leading integrated global pharmaceutical company, today confirmed that it has received a favorable decision from the U.S. Court of Appeals for the Federal Circuit related to its ongoing patent challenge in connection with Watson's Abbreviated New Drug Application seeking FDA approval to market a generic version of Teva Women's Health, Inc.'s SEASONIQUE and ethinyl estradiol.

28 Mar 2011

Study finds only 1 in 10 children with asthma use traditional inhalers correctly

Fewer than one in 10 children with asthma use traditional inhalers correctly, according to a new study from the University of North Carolina at Chapel Hill.

28 Mar 2011

Geriatrician provides latest Alzheimer drug research developments at International conference

Drugs that can stop or reverse Alzheimer's disease progression are not available yet, but a number of potentially promising clinical trials could hold the key for modifying the treatment of the disease.

28 Mar 2011

APP voluntarily recalls Irinotecan Hydrochloride Injection for precautionary measure

APP Pharmaceuticals, Inc., announced today that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer.

28 Mar 2011

NeoProteomics secures exclusive option agreement with Case Western Reserve University

NeoProteomics Inc., a biomarker development and software company, has secured an exclusive option agreement with Case Western Reserve University. The deal has potential to enhance various forms of treatment of cancer, diabetes, and inflammatory diseases.

28 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program.

25 Mar 2011

US District Court rules against Watson in generic Fentora patent suit

Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora® (fentanyl buccal tablets C-II) infringes United States Patent No. 6,264,981 (the '981 Patent). The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.

25 Mar 2011

Merck to return rights for betrixaban to Portola

Portola Pharmaceuticals and Merck, known as MSD outside the United States and Canada, today announced that Merck plans to return to Portola all rights for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation (SPAF). This decision was made following a review of Merck's investigational portfolio.

25 Mar 2011

Biostar fourth quarter revenues increase 65.7% to $28.2 million

Biostar Pharmaceuticals, Inc., Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results for the fourth quarter and full year ended December 31, 2010.

25 Mar 2011

Graceway receives FDA approval for Zyclara Cream to treat genital warts

Graceway Pharmaceuticals announced today that the Food and Drug Administration has approved Zyclara Cream for the treatment of external genital and perianal warts in patients 12 years of age and older.

25 Mar 2011

EU supports new collaborative research projects on tuberculosis

It's March 24th again and the World Tuberculosis Day reminds us that for almost 50 years no new drugs have been developed against this terrible disease, which is currently killing nearly two million people worldwide each year. It's a global problem because the emergence of drug resistant strains of this infectious disease - normally associated with poverty - is a growing problem even in high-income economies.

25 Mar 2011

Pharmaceuticals News and Research

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

MolecularMD and ARIAD collaborate to develop and commercialize CML, ALL diagnostic test

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

A.P. Pharma fourth quarter revenue decreases to $1.6 million

University of Aberdeen, TPP enter agreement to develop novel future medicines

Anergis SA closes funding round for allergy vaccines

U.S. District Court rules in favor of Watson in generic SEASONIQUE patent infringement suit

Study finds only 1 in 10 children with asthma use traditional inhalers correctly

Geriatrician provides latest Alzheimer drug research developments at International conference

APP voluntarily recalls Irinotecan Hydrochloride Injection for precautionary measure

NeoProteomics secures exclusive option agreement with Case Western Reserve University

Study finds increased risk of VTE during first year of combination oral contraceptive usage

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

US District Court rules against Watson in generic Fentora patent suit

Merck to return rights for betrixaban to Portola

Biostar fourth quarter revenues increase 65.7% to $28.2 million

Graceway receives FDA approval for Zyclara Cream to treat genital warts

EU supports new collaborative research projects on tuberculosis

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence